Clinical follow-up on the development of impulse control disorders in Parkinson's disease

Completed

• Conditions: impulsscontrolestoornissen; shaking palsy; 10028037; 10027946

• Registration Number: NL-OMON47691
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

medication-naive (de novo) Parkinson's disease patients who underwent a
dopamine transporter SPECT scan and MRI scan at baseline in the VU University
medical center.

Exclusion Criteria

use of medication at baseline that influences DaT tracer binding (including
serotonin reuptake inhibitors).

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Striatal dopamine transporter availability (measured with DaT SPECT) at<br /><br>baseline<br /><br>- presence and severity of symptoms of impulse control disorders at baseline<br /><br>and follow-up</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- course of the symptoms of depression, anxiety, impulsivity and executive<br /><br>functioning with progression of the disease and possible effects of treatment.<br /><br>- temporal relation between the symptoms of depression, anxiety, impulsivity<br /><br>and cognitive functioning.</p><br>